Skip to content
Infectious Disease

Resources for Public Health

*NOTICE of PRI​FTIN® (RIFAPENTINE) impurity issue 7-1-20*
In June 2020 Sanofi alerted the Division of Tuberculosis Elimination, other health agencies, and stakeholders worldwide about a newly detected impurity in Priftin®. The impurity, 1-cyclopentyl-4-nitrosopiperazine, is a nitrosamine and a potential carcinogen.  Read more at the links below.

Letter to Alaska providers/public health nurses​​​

Information from CDC​​


Alaska TB Manual